Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA.
Curr Oncol Rep. 2011 Feb;13(1):26-36. doi: 10.1007/s11912-010-0138-8.
Primary brain tumors are a heterogeneous group of malignancies with highly variable outcomes, and diagnosis is largely based on the histological appearance of the tumors. However, the diversity of primary brain tumors has made prognostic determinations based purely on clinicopathologic variables difficult. There is an increasing body of data suggesting a significant amount of molecular diversity accounts for the heterogeneity of clinical observations, such as response to treatment and time to progression. The last decade has witnessed an explosive advance in our knowledge of the molecular genetics of brain tumors, due in large part to the availability of high-throughput profiling techniques and to the completion of the human genome sequencing project. The large amount of data generated by these efforts has enabled the identification of prognostic and predictive factors and helping to identify pathways which are driving tumor growth. Identification of biomarkers will enable better patient stratification and individualization of treatment.
原发性脑肿瘤是一组异质性恶性肿瘤，其预后差异很大，诊断主要基于肿瘤的组织学表现。然而，原发性脑肿瘤的多样性使得仅基于临床病理变量进行预后判断变得困难。越来越多的数据表明，大量的分子多样性解释了临床观察的异质性，例如对治疗的反应和进展时间。过去十年，由于高通量分析技术的应用和人类基因组测序项目的完成，我们对脑肿瘤的分子遗传学有了突破性的认识。这些努力产生的大量数据使我们能够确定预后和预测因素，并有助于确定驱动肿瘤生长的途径。鉴定生物标志物将能够更好地对患者进行分层，并对治疗进行个体化。
